Clinical Trial

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-27; most recent amendment 2026-03-03.
Trial Details
NCT Number NCT06857279
Lead Sponsor Shanghai Henlius Biotech
Conditions Carcinoma of Head and/or Neck
Enrollment 167 participants
Start Date 2025-04-22
Primary Completion 2027-12-30 (estimated)
Study Completion 2029-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-05